Document is current
Any future updates will be listed below
-
Authors
Lammi, Matthew R.
Mukherjee, Monica
Saketkoo, Lesley Ann
Carey, Kyle
Hummers, Laura
Hsu, Steven
Krishnan, Amita
Sandi, Marie
Shah, Ami A.
Zimmerman, Stefan L.
Hassoun, Paul M.
Mathai, Steven C.
-
Funding
Funding for this research was provided by:
U.S. Department of Defense
- License Information
-
More Information
Article History
Received: 29 June 2023
Accepted: 1 February 2024
First Online: 30 April 2024
Declarations
:
: The SEPVADIS trial was approved (IRB # 00265164) by the IRB at Johns Hopkins University, which serves as the sIRB for both recruiting sites.
: N/A.
: MRL: Clinical trial participation with Gilead, Actelion/Janssen, Bayer, United Therapeutics, Altavant, Acceleron (all funds to the institution). MM: Data Safety Monitoring Board, Advarra, Inc. AS: Clinical trial grants (paid to the institution) from Kadmon Corporation, Eicos Sciences Inc, Arena Pharmaceuticals and Medpace LLC. SZ: Siemens Healthcare - partial salary support for consultation. PMH: Serves on a scientific steering committee for Merck and Co, and as an advisor for Tectonic, activities unrelated to the current work. Nothing to declare: LAS, KC, MS, AK, LH, SH, SCM.
